Angiotensin IV (Ang IV, Ang 3-8) is a six-amino acid peptide (Val-Tyr-Ile-His-Pro-Phe) generated by the sequential enzymatic processing of angiotensin II through angiotensin III. Once dismissed as an inactive degradation product at the tail end of the RAAS cascade, Ang IV was recognized in the early 1990s as a potent neuroactive peptide when it was shown to enhance memory performance in passive avoidance and spatial learning tasks — effects mediated not through classical AT1 or AT2 receptors, but through a novel binding site designated the AT4 receptor.

Overview

Angiotensin IV represents the terminal bioactive peptide of the classical RAAS degradation cascade: angiotensinogen to angiotensin I (by renin), to angiotensin II (by ACE), to angiotensin III (by aminopeptidase A), and finally to angiotensin IV (by aminopeptidase N). While each step was historically viewed as progressive inactivation, the discovery that Ang IV possesses potent cognitive-enhancing properties through a unique receptor system revealed that the RAAS extends far beyond cardiovascular regulation into neuroscience.

The AT4 receptor was identified by Albiston et al. (2001) as IRAP — a type II transmembrane aminopeptidase that is co-localized with GLUT4 glucose transporter vesicles in insulin-responsive tissues, and with dendritic vesicles in hippocampal neurons [1]. Ang IV binds to the catalytic site of IRAP as a competitive inhibitor, preventing the degradation of IRAP's endogenous substrates — which include memory-relevant neuropeptides such as vasopressin, oxytocin, somatostatin, and cholecystokinin. By inhibiting IRAP, Ang IV prolongs the action of these pro-cognitive neuropeptides in the synaptic environment, providing a compelling mechanistic explanation for its memory-enhancing effects.

This mechanism has made IRAP a high-value drug target for cognitive disorders, including Alzheimer's disease, age-related cognitive decline, and traumatic brain injury. Metabolically stable Ang IV analogs — most notably Nle1-Ang IV (Norleucine-substituted Ang IV) and the peptidomimetic IRAP inhibitors developed by the Chai and Albiston laboratories — have demonstrated robust cognitive enhancement in preclinical models with improved pharmacokinetic properties compared to native Ang IV.

Mechanism of Action

Angiotensin IV operates through a mechanism fundamentally distinct from the classical AT1/AT2 receptor signaling of angiotensin II:

AT4 Receptor (IRAP) Inhibition

The AT4 receptor was identified as insulin-regulated aminopeptidase (IRAP), a 160 kDa zinc-dependent metalloprotease (aminopeptidase M1 family). Ang IV binds competitively to the catalytic site of IRAP, inhibiting its enzymatic activity with nanomolar affinity. IRAP normally degrades several bioactive peptides:

• Vasopressin (AVP): Involved in memory consolidation and social recognition.
• Oxytocin: Implicated in social memory and learning.
• Somatostatin: Modulates hippocampal excitability and memory processes.
• Cholecystokinin (CCK-8): Participates in anxiety, satiety, and memory.
• Met-enkephalin: Opioid peptide involved in reward and memory.

By inhibiting IRAP, Ang IV extends the half-life and local concentration of these neuropeptides in the hippocampal synaptic cleft, enhancing their pro-cognitive effects. This "substrate accumulation" hypothesis, proposed by Albiston et al. and supported by subsequent studies, is the leading mechanistic model for Ang IV's cognitive effects [1, 2].

Hippocampal Long-Term Potentiation (LTP)

Ang IV facilitates hippocampal LTP — the cellular mechanism underlying learning and memory formation. Intracerebroventricular (ICV) Ang IV administration enhances LTP magnitude in the CA1 region of the hippocampus, as demonstrated by Kramár et al. (2001) using electrophysiological recordings in rat hippocampal slices [3].

The LTP facilitation involves:

• Enhanced NMDA receptor-mediated calcium influx.
• Increased dendritic protein synthesis through mTOR pathway activation.
• Augmented AMPA receptor trafficking to postsynaptic membranes.
• Elevated BDNF signaling in hippocampal circuits.

GLUT4 Translocation and Glucose Uptake

IRAP is physically associated with GLUT4 vesicles in insulin-responsive tissues (adipose tissue, skeletal muscle) and in hippocampal neurons. Ang IV-mediated IRAP inhibition may promote GLUT4 translocation to the cell surface, enhancing glucose uptake in hippocampal neurons. This provides an additional mechanism for cognitive enhancement, as hippocampal glucose utilization is critical for memory formation and is impaired in Alzheimer's disease [4].

Hepatocyte Growth Factor (HGF) / c-Met Signaling

An alternative mechanism proposed by Wright and Harding suggests that Ang IV (and particularly its analog LVV-hemorphin-7, which also binds AT4) may enhance HGF/c-Met signaling in the hippocampus, promoting neuronal survival, neurite outgrowth, and synaptic plasticity. This mechanism may operate in parallel with IRAP inhibition, and the relative contribution of each pathway remains under investigation [5].

Renal Effects

In the kidney, Ang IV increases renal cortical blood flow through mechanisms that appear distinct from AT1 and AT2 signaling. AT4/IRAP is expressed in the renal cortex, particularly in proximal tubular cells and cortical vasculature. Ang IV-mediated increases in cortical blood flow may involve NO-dependent vasodilation and may oppose Ang II-mediated efferent arteriolar constriction [6].

Reconstitution Calculator

Research

Safety Profile

Angiotensin IV is an endogenous peptide present in physiological concentrations in the brain and periphery. Its safety profile in preclinical research settings has been favorable:

• No cardiovascular toxicity: Unlike Ang II, Ang IV does not produce significant vasoconstriction or hypertension at doses used for cognitive enhancement. It has negligible affinity for AT1 receptors at physiological concentrations.
• No sedation or behavioral toxicity: Cognitive doses of Ang IV and analogs do not produce sedation, motor impairment, or anxiogenic effects in rodent behavioral studies.
• Selectivity: AT4/IRAP selectivity minimizes off-target effects on the classical RAAS axis.
• Analog safety: Nle1-Ang IV and dihexa have shown acceptable safety profiles in preclinical toxicology studies, though formal Phase I human data are limited.
• Theoretical concerns: IRAP is involved in GLUT4 trafficking and peptide hormone processing; chronic inhibition could theoretically affect glucose homeostasis or neuropeptide signaling. Long-term safety studies are needed.

Clinical Research Protocols

• ICV administration (animal research): 0.1-10 nmol bolus injection for acute cognitive studies; 1-100 pmol continuous infusion via minipump for chronic studies [7, 8].
• Nle1-Ang IV (animal research): 1-10 nmol ICV; systemic dosing under investigation with modified formulations.
• Dihexa: 0.01-1 mg/kg oral or IP in rodent studies; blood-brain barrier-penetrant [9].
• IRAP inhibitors (HFI series): 1-10 mg/kg oral in rodent behavioral studies [10].
• No standardized human clinical trial protocols have been established for Ang IV or its analogs.

Subpopulation Research

• Aged animals: Ang IV and analogs reverse age-related cognitive decline in multiple rodent behavioral paradigms, restoring performance to young adult levels [7, 8].
• Scopolamine-impaired models: Ang IV reverses anticholinergic-induced memory deficits, demonstrating interaction with cholinergic circuitry [8].
• AD transgenic mice: Limited data in amyloid transgenic models; dihexa has shown synaptic rescue in aged animals with cognitive impairment [9].
• Renal ischemia models: Ang IV-mediated cortical blood flow enhancement may protect against ischemic renal injury [6].

Pharmacokinetic Profile

Ongoing & Future Research

• IRAP crystallography and drug design: High-resolution IRAP crystal structures are enabling rational design of potent, selective, orally bioavailable inhibitors with optimized pharmacokinetics [10].
• Clinical translation: Dihexa and HFI-series compounds are in preclinical development for Alzheimer's disease and age-related cognitive decline. First-in-human studies have not yet been reported.
• Combination AD therapy: IRAP inhibitors combined with anti-amyloid antibodies (aducanumab, lecanemab) or anti-tau therapies as multi-target AD treatment strategies.
• Traumatic brain injury: Ang IV's LTP-enhancing and neuroprotective properties are being investigated for post-TBI cognitive rehabilitation.
• IRAP as biomarker: Soluble IRAP levels in cerebrospinal fluid as a potential biomarker for cognitive decline and AD progression.
• Metabolic-cognitive links: Exploring the relationship between IRAP, GLUT4, insulin resistance, and cognitive decline in type 2 diabetes and metabolic syndrome.